Table 1.
Characteristics of 1186 people with SARS-CoV-2 infections stratified by survival.
| Variables | Total (n = 1186) |
Survived (n = 1026) |
Died (n = 160) |
p-Value | ||
|---|---|---|---|---|---|---|
| Males, n (%) | 644 (54.3) | 545 (53.1) | 99 (61.9) | 0.04 | ||
| Median (IQR) age, years | 74 (62–83) | 73 (60–83) | 81.5 (70–88) | <0.0001 | ||
| Median (IQR) 4C score | 10 (6–12) | 9 (6–12) | 13 (11–16) | <0.0001 | ||
| 4C risk groups | Low (0–3) | 137 (11.6) | 136 (13.3) | 1 (0.6) | <0.0001 | |
| Intermediate (4–8) | 302 (25.5) | 289 (28.2) | 13 (8.1) | |||
| High (9–14) | 596 (50.3) | 513 (50.0) | 83 (51.9) | |||
| Very high (≥ 15) | 151 (12.7) | 88 (8.6) | 63 (39.4) | |||
| Respiratory rate | < 20 | 788 (66.4) | 723 (70.5) | 65 (40.6) | <0.0001 | |
| 20–29 | 296 (25.0) | 241 (23.5) | 55 (34.4) | |||
| ≥ 30 | 102 (8.6) | 62 (6.0) | 102 (8.6) | |||
| Glasgow Coma Scale < 15 | 219 (18.5) | 156 (15.2) | 63 (39.4) | <0.0001 | ||
| Peripheral oxygen < 92% | 218 (18.4) | 155 (15.1) | 63 (39.4) | <0.0001 | ||
| BMI > 30 kg/m2, n (%) | 291 (24.5) | 251 (24.5) | 40 (25.0) | 0.88 | ||
| Chronic renal disease, n (%) | 195 (16.4) | 155 (15.1) | 40 (25.0) | 0.002 | ||
| Rheumatological disease, n (%) | 63 (5.3) | 60 (5.9) | 3 (1.9) | 0.04 | ||
| Decompensated diabetes, n (%) | 180 (15.2) | 149 (14.5) | 31 (19.4) | 0.11 | ||
| Diabetes, n (%) | 264 (22.3) | 224 (21.8) | 40 (25.0) | 0.37 | ||
| Chronic liver disease, n (%) | 67 (5.7) | 54 (5.3) | 13 (8.1) | 0.14 | ||
| COPD/emphysema, n (%) | 237 (20.0) | 193 (18.8) | 44 (27.5) | 0.01 | ||
| Hemoglobinopathies, n (%) | 5 (0.4) | 5 (0.5) | 0 (0.0) | 1.00 | ||
| Neurodevelopmental/neurodegenerative diseases, n (%) | 315 (26.6) | 251 (24.5) | 64 (40.0) | <0.0001 | ||
| Dementia, n (%) | 177 (14.9) | 132 (12.9) | 45 (28.1) | <0.0001 | ||
| Cerebrovascular events, n (%) | 133 (11.2) | 110 (10.7) | 23 (14.4) | 0.17 | ||
| Oncological disease, n (%) | 209 (17.6) | 177 (17.3) | 32 (20.0) | 0.40 | ||
| Hematological tumors, n (%) | 76 (6.4) | 59 (5.8) | 17 (10.6) | 0.02 | ||
| Solid tumors in chemotherapy, n (%) | 33 (2.8) | 29 (2.8) | 4 (2.5) | 1.00 | ||
| Hematological tumors in chemotherapy, n (%) | 55 (4.6) | 42 (4.1) | 13 (8.1) | 0.02 | ||
| Cardiovascular diseases, n (%) | 452 (38.1) | 366 (35.7) | 86 (53.8) | <0.0001 | ||
| Heart failure, n (%) | 403 (34.0) | 321 (31.4) | 82 (51.3) | <0.0001 | ||
| Previous myocardial infarction, n (%) | 146 (12.3) | 126 (12.3) | 20 (12.5) | 0.94 | ||
| Median (IQR) number of comorbidities | 2 (1–3) | 2 (1–3) | 3 (2–4) | <0.0001 | ||
| Vaccine, n (%) | 938 (79.1) | 826 (80.5) | 112 (70.0) | 0.002 | ||
| N. Vaccine doses, n (%) | 0 | 248 (20.9) | 200 (19.5) | 48 (30.0) | 0.02 | |
| 1 | 32 (2.7) | 26 (2.5) | 6 (3.8) | |||
| 2 | 208 (17.5) | 179 (17.5) | 29 (18.1) | |||
| 3 | 676 (57.0) | 601 (58.6) | 75 (46.9) | |||
| 4 | 22 (1.9) | 20 (2.0) | 2 (1.3) | |||
| Median (IQR) time, last dose | 128.5 (76–186) | 127 (76–181) | 151.5 (81–223.5) | 0.02 | ||
| In-hospital infection, n (%) | 256 (21.6) | 211 (20.6) | 45 (28.1) | 0.03 | ||
| Symptoms | ||||||
| Fever, n (%) | 569 (48.0) | 486 (47.4) | 83 (51.9) | 0.29 | ||
| Cough, n (%) | 455 (38.4) | 383 (37.3) | 72 (45.0) | 0.06 | ||
| Pharyngodynia, n (%) | 160 (13.5) | 146 (14.2) | 14 (8.8) | 0.06 | ||
| Asthenia, n (%) | 389 (32.8) | 330 (32.2) | 59 (36.9) | 0.24 | ||
| Headache, n (%) | 136 (11.5) | 125 (12.2) | 11 (6.9) | 0.05 | ||
| Myalgia, n (%) | 184 (15.5) | 160 (15.6) | 24 (15.0) | 0.85 | ||
| Gastrointestinal symptoms, n (%) | 167 (14.1) | 149 (14.5) | 18 (11.3) | 0.27 | ||
| Dyspnea, n (%) | 380 (32.0) | 292 (28.5) | 88 (55.0) | <0.0001 | ||
| Anosmia, n (%) | 22 (1.9) | 19 (1.9) | 3 (1.9) | 1.00 | ||
| CT findings | ||||||
| GGO, n (%) | 451 (39.8) | 355 (36.4) | 96 (60.8) | <0.0001 | ||
| Consolidation, n (%) | 275 (24.3) | 206 (21.1) | 69 (43.7) | <0.0001 | ||
| Pulmonary embolism, n (%) | 25 (2.1) | 21 (2.1) | 4 (2.5) | 0.77 | ||
| Laboratory examination | ||||||
| Median (IQR) urea | 37 (28–60) | 35 (27–55) | 60.5 (36.5–110.0) | <0.0001 | ||
| Median (IQR) CRP | 3 (1.3–7.7) | 2.5 (1.1–6.6) | 8.6 (3.8–16.0) | <0.0001 | ||
IQR: interquartile range; BMI: body mass index; COPD: chronic obstructive pulmonary disease; CT: computer tomography; GGO: ground-glass opacity; CRP: C-reactive protein.